公开(公告)号：US12128113B2

公开(公告)日：2024-10-29

申请号：US16302607

申请日：2017-05-18

申请人： ModernaTX, Inc.

发明人： Kerry Benenato ,  Stephen Hoge ,  Paolo Martini ,  Iain Mcfadyen ,  Vladimir Presnyak ,  Ding An ,  Ellalahewage Sathyajith Kumarasinghe

IPC分类号： A61K48/00 ,  A61K9/00 ,  A61K9/51 ,  A61K47/00 ,  A61K47/14 ,  A61K47/16 ,  A61K47/22 ,  A61K47/24 ,  C12N15/88 ,  A61K9/127 ,  A61K47/10 ,  A61K47/28 ,  C07K14/705

CPC分类号： A61K48/0066 ,  A61K9/51 ,  A61K47/14 ,  A61K47/16 ,  A61K47/22 ,  A61K47/24 ,  A61K48/0041 ,  C12N15/88 ,  A61K9/1271 ,  A61K9/5123 ,  A61K47/10 ,  A61K47/28 ,  C07K14/705

摘要： The invention relates to mRNA therapy for the treatment of Alagille syndrome (ALGS), mRNAs for use in the invention, when administered in vivo, encode JAGGED 1 (JAG1), isoforms thereof functional fragments thereof, and fusion proteins comprising JAG1, mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of JAG1 expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient JAG1 activity in subjects.

公开(公告)号：US12070454B1

公开(公告)日：2024-08-27

申请号：US18432297

申请日：2024-02-05

申请人： PFOF LLC

发明人： Howard L. Howell ,  Ralf Blackstone

IPC分类号： A61M19/00 ,  A61K31/445 ,  A61K31/573 ,  A61K45/06 ,  A61K47/00 ,  A61K47/02

CPC分类号： A61K31/445 ,  A61K31/573 ,  A61K45/06 ,  A61K47/02

摘要： An improved anesthetic nerve block and method is disclosed comprising a local long acting anesthetic and a physiologic carbonate base. The local long acting anesthetic and the physiologic carbonate base are introduced to a living organism and adjacent to a nerve. The local long acting anesthetic and the physiologic carbonate base react to form a precipitated mass around the nerve for creating a local nerve block. The precipitated mass degrades into unionized local anesthetic which penetrates through the nerve membrane and into the axon for creating a prolonged local nerve block.

公开(公告)号：US20240207306A1

公开(公告)日：2024-06-27

申请号：US18594618

申请日：2024-03-04

申请人： KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION

发明人： Kazunori KATAOKA ,  Shigehito OSAWA ,  Satoshi UCHIDA ,  Kotaro HAYASHI ,  Anjaneyulu DIRISALA ,  Kazuko TOH

IPC分类号： A61K31/74 ,  A61K31/25 ,  A61K47/00

CPC分类号： A61K31/74 ,  A61K31/25 ,  A61K47/00

摘要： The present invention provides a composition that controls pharmacokinetics. Specifically, the present invention provides: a composition for controlling pharmacokinetics, the composition containing a polyvalent cation as an active ingredient; and a method for controlling pharmacokinetics using the polyvalent cation.

公开(公告)号：US11986538B2

公开(公告)日：2024-05-21

申请号：US17557886

申请日：2021-12-21

申请人： The Johns Hopkins University

发明人： Alyssa K. Kosmides ,  Jonathan P. Schneck

IPC分类号： A61K47/00 ,  A61K9/00 ,  A61K9/51 ,  A61K39/395 ,  A61K47/68 ,  A61K47/69 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783 ,  A61K39/00

CPC分类号： A61K47/6939 ,  A61K9/0009 ,  A61K9/0019 ,  A61K9/5161 ,  A61K39/395 ,  A61K39/3955 ,  A61K47/6849 ,  A61K47/6873 ,  A61P35/00 ,  C07K16/2827 ,  C07K16/2878 ,  C12N5/0638 ,  A61K2039/507 ,  C07K2317/75 ,  C07K2317/76 ,  A61K39/3955 ,  A61K2300/00

摘要： The presently disclosed subject matter relates to immunoswitch particles that switch off immunosuppressive pathways on tumor cells or immunosuppressive molecules induced by tumor cells in the tumor microenvironment, or virus infected cells or immunosuppressive molecules induced by virus infected cells in the microenvironment surrounding the virus infected cells, while simultaneously switching on co-stimulatory or co-inhibitory pathways on T cells, as well as method for converting immunosuppressive signals in cells, tissues, and subjects into stimulatory signals, and immunotherapy-based methods for treating cancer and chronic viral infections.

公开(公告)号：US20240050518A1

公开(公告)日：2024-02-15

申请号：US18335893

申请日：2023-06-15

申请人： SANOFI

发明人： Gary J. Nabel ,  Chih-Jen Wei ,  Laura Nguyen ,  Kurt Swanson ,  Te-Hui Chou ,  Stefan Koester

IPC分类号： A61K38/16 ,  A61K47/00 ,  C07K14/05

CPC分类号： A61K38/162 ,  A61K47/00 ,  C07K14/05 ,  C07K2319/00

摘要： This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.

公开(公告)号：US11891668B2

公开(公告)日：2024-02-06

申请号：US17514724

申请日：2021-10-29

申请人： The University of Kansas ,  Kansas State University Research Foundation

发明人： Mei He

IPC分类号： A61K47/00 ,  C12Q1/6886 ,  A61K47/69 ,  G01N33/574 ,  G01N33/543 ,  B03C1/015 ,  B03C1/30 ,  B01L3/00 ,  A61K49/00

CPC分类号： C12Q1/6886 ,  A61K47/6901 ,  A61K49/0097 ,  B01L3/502715 ,  B01L3/502761 ,  B03C1/015 ,  B03C1/30 ,  G01N33/5434 ,  G01N33/54333 ,  G01N33/574 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N2446/80

摘要： Methods for producing engineered exosomes and other vesicle-like biological targets, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.

公开(公告)号：US11845740B2

公开(公告)日：2023-12-19

申请号：US16472172

申请日：2018-05-24

申请人： OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”

发明人： Vladimir Evgenievich Nebolsin ,  Anastasia Vladimirovna Rydlovskaya ,  Tatyana Alexandrovna Kromova

IPC分类号： C07D403/12 ,  A61P25/02 ,  A61P37/00 ,  A61P1/00 ,  A61P29/00 ,  A61K31/4178 ,  A61P11/00 ,  A61P13/12 ,  A61P17/06 ,  A61K47/00 ,  A61K45/06 ,  A61P3/04 ,  A61P11/06 ,  A61P17/00 ,  C12N9/10

CPC分类号： C07D403/12 ,  A61P25/02 ,  A61P37/00 ,  C12N9/104 ,  C12Y203/02005

摘要： The invention relates to chemistry of organic substances, pharmacology and medicine, and concerns treating diseases associated and with aberrant activity of cells of the immune system, more particularly for treating lung, respiratory tract and abdominal diseases, radiation sickness and pain syndrome, and also other diseases by using compounds of formula (A)






wherein
R1 is —C(O)—R2—(O)— or —R2—C(O)— group, where R2 is —(CH2)n-group optionally substituted with one or two C1-C6 alkyls, or phenyl,
n is an integer from 0 to 4;
wherein compounds are selected from the group consisting of the group of compounds as set out in the description. These compounds, as well as pharmaceutically acceptable salts thereof, are highly effective in inhibiting glutaminyl cyclase, which is involved, in particular, in processes of post-translational modification of chemokines and chemotaxis of monocytes, macrophages and other cells of the immune system. This invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of the compounds of formula (A) as defined above.

公开(公告)号：US11717562B2

公开(公告)日：2023-08-08

申请号：US16210248

申请日：2018-12-05

申请人： AERase, Inc.

发明人： Scott W. Rowlinson ,  Anthony G. Quinn ,  Ann Lowe ,  David Lowe

IPC分类号： A61K38/00 ,  A61K47/00 ,  A61K38/50 ,  A61K9/00 ,  A61K48/00 ,  A61K45/06 ,  A61P3/00 ,  A61K47/60 ,  A61K38/51

CPC分类号： A61K38/50 ,  A61K9/0019 ,  A61K38/51 ,  A61K45/06 ,  A61K47/60 ,  A61K48/005 ,  A61P3/00 ,  C12Y305/03001

摘要： A method and composition to treat a subject with arginase 1 (ARG1) deficiency (ARG1-D) and to rapidly reduce the levels of at least one of arginine and/or a guanidino compound in the subject.

公开(公告)号：US20230201370A1

公开(公告)日：2023-06-29

申请号：US18057359

申请日：2022-11-21

申请人： Evox Therapeutics Ltd. ,  Oxford University Innovation Limited

发明人： Justin HEAN ,  Imre MAGER ,  Matthew WOOD ,  Samir EL ANDALOUSSI ,  Oscar WIKLANDER ,  Joel NORDIN

IPC分类号： A61K48/00 ,  A61K47/65 ,  A61K41/00 ,  A61K47/64 ,  A61K47/00 ,  A61K9/127

CPC分类号： A61K48/0008 ,  A61K47/65 ,  A61K41/0042 ,  A61K47/6425 ,  A61K47/00 ,  A61K9/127 ,  A61K48/005 ,  A61K48/0091

摘要： The present invention pertains to an inventive release mechanism for extracellular vesicle (EV)-mediated intracellular and intramembrane delivery of therapeutic polypeptides. More specifically, the invention relates to EVs comprising polypeptide constructs which comprise a therapeutic polypeptide releasably attached to an exosomal polypeptide. Furthermore, the present invention pertains to manufacturing methods, pharmaceutical compositions, medical uses and applications, and various other embodiments related to the inventive EVs.

公开(公告)号：US11654195B2

公开(公告)日：2023-05-23

申请号：US17786980

申请日：2020-11-26

申请人： Jin Wang Kim ,  Jung Ok Lee ,  Hyun Ji Kim ,  Hyun Woo Kim

发明人： Jin Wang Kim ,  Jung Ok Lee ,  Hyun Ji Kim ,  Hyun Woo Kim

IPC分类号： A61K47/00 ,  A61P35/00 ,  A61K41/00 ,  A61K47/69 ,  A61K47/61

CPC分类号： A61K41/0057 ,  A61K47/61 ,  A61K47/6939 ,  A61P35/00

摘要： The present invention provides an eco-friendly smart photosensitizer comprising a conjugate of hydroxypropyl methylcellulose and porfimer sodium photosensitizer, and a photo-stem cell therapy product comprising the photosensitizer. The photosensitizer of the present invention can be advantageously used in various fields including anticancer therapy, stem cell therapy, and the like, without side effects.